# BridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ET
Canonical URL: https://biopharmsignal.com/news/BBIO/bridgebio-to-report-first-quarter-2026-financial-results-and-commercial-updates--b152d46d
Ticker: BBIO
Company: BridgeBio
Source: BridgeBio
Published: 2026-04-30 11:30 EST
## Summary

BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company...

## Article Body
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that it will release its first quarter 2026 financial results and business update after the market closes on Thursday, May 7, 2026. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day.

To access the live webcast of BridgeBio’s presentation, please visit the “Events & Presentations” page within the Investors section of the BridgeBio website at investor.bridgebio.com/events-and-presentations/ . A replay of the webcast will be available on the BridgeBio website for 30 days following the event.

Participants may access the webcast by registering online using the following link, here .

About BridgeBio Pharma, Inc. BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn , X , Facebook , Instagram , YouTube , and TikTok .

BridgeBio Media Contact: Bubba Murarka, Executive Vice President contact@bridgebio.com (650)-789-8220

BridgeBio Investor Contact: Chinmay Shukla, Senior Vice President, Strategic Finance ir@bridgebio.com
## Recent Company News
- 2026-07-22 11:30 EST — [BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1](https://biopharmsignal.com/news/BBIO/bridgebio-announces-fda-acceptance-of-nda-for-encaleret-for-adh1-c90bb02f) — Source: BridgeBio
- 2026-07-10 20:01 EST — [BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-02809453) — Source: BridgeBio
- 2026-07-02 11:30 EST — [Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM](https://biopharmsignal.com/news/BBIO/acoramidis-associated-with-first-ever-early-and-sustained-direct-kidney-protecti-a72e923d) — Source: BridgeBio
- 2026-07-01 11:30 EST — [BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches](https://biopharmsignal.com/news/BBIO/bridgebio-raises-1-billion-in-preferred-equity-to-accelerate-present-and-upcomin-7cd369f3) — Source: BridgeBio
- 2026-06-28 20:00 EST — [BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia](https://biopharmsignal.com/news/BBIO/bridgebio-announces-publication-in-the-new-england-journal-of-medicine-of-phase--239e7199) — Source: BridgeBio
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)